SS-31 (Elamipretide): Mechanism, Evidence, and Clinical Status

What Is SS-31 and Why Does It Matter?

SS-31 is a water-soluble, cell-permeable peptide designed to reach the inner mitochondrial membrane within minutes of administration. Its relevance extends across cardiology, neurology, and rare disease because mitochondrial dysfunction sits at the root of conditions ranging from heart failure to primary mitochondrial myopathy 1. The peptide was developed by Hazel Szeto and Peter Bhatt at Weill Cornell, giving rise to the "SS" (Szeto-Schiller) naming convention.

The Cardiolipin Connection

Cardiolipin is a phospholipid found almost exclusively on the inner mitochondrial membrane. It anchors cytochrome c and stabilizes the electron transport chain complexes I, III, and IV. When cardiolipin becomes oxidized or is deficient (as in Barth syndrome, caused by tafazzin gene mutations), electron leak increases and ATP production falls 2.

SS-31 binds selectively to cardiolipin through electrostatic and hydrophobic interactions. This binding prevents cytochrome c peroxidase activity and preserves normal electron flow, which in turn reduces superoxide generation 3. The peptide does not function as a conventional antioxidant that scavenges free radicals after they form. Instead, it limits ROS production at the source.

How SS-31 Differs from Other Antioxidants

Coenzyme Q10, MitoQ, and idebenone all target mitochondrial oxidative stress, but they operate downstream. SS-31 acts upstream by stabilizing the cardiolipin-cytochrome c complex and preventing electron leak before superoxide is generated. Preclinical data in aged mouse hearts demonstrated that a single SS-31 infusion restored state 3 respiration and reduced hydrogen peroxide emission to levels seen in young controls within one hour 4.

Mechanism of Action: Step by Step

The peptide carries a net charge of +3 at physiological pH, which drives its accumulation across the mitochondrial membrane potential in a concentration-dependent manner. Within minutes of subcutaneous injection, SS-31 reaches mitochondria at concentrations roughly 1,000- to 5,000-fold above extracellular levels 1.

Binding and Stabilization

Once inside the inner membrane, SS-31 interacts with cardiolipin via two mechanisms. The dimethyltyrosine (Dmt) residue inserts into the hydrophobic core of the lipid bilayer, while the arginine and lysine residues form salt bridges with the phosphate head groups of cardiolipin. This dual anchoring prevents cardiolipin from peroxidizing and preserves the cristae architecture needed for efficient oxidative phosphorylation 3.

Downstream Effects

By maintaining electron transport chain efficiency, SS-31 reduces mitochondrial ROS, preserves membrane potential, and inhibits mitochondrial permeability transition pore (mPTP) opening. In ischemia-reperfusion models, this translated to 50 to 60% reductions in infarct size in rat and sheep hearts 5. The prevention of mPTP opening also reduces cytochrome c release into the cytosol, limiting apoptotic signaling.

Clinical Trial Evidence

SS-31 has entered human trials across multiple indications. None has resulted in FDA approval as of May 2026, but the data define both the peptide's promise and its limitations.

TAZPOWER: Barth Syndrome

The TAZPOWER trial (NCT03098797) enrolled 12 patients with genetically confirmed Barth syndrome. Subjects received elamipretide 40 mg subcutaneously once daily for 12 weeks in a double-blind, crossover design. The primary endpoint, change in six-minute walk test (6MWT) distance, showed a mean improvement of 29.6 meters over placebo. Stroke volume measured by cardiac MRI also improved 6.

Despite these signals, Stealth BioTherapeutics submitted an NDA that the FDA responded to with a Complete Response Letter in February 2023, citing the small sample size and requesting additional evidence of clinical benefit 7. The open-label extension (TAZPOWER-OLE) showed sustained 6MWT gains at 168 weeks, but the path to approval remains uncertain.

EMBRACE: Heart Failure with Reduced Ejection Fraction

EMBRACE (NCT02788747) randomized 71 patients with heart failure and left ventricular ejection fraction <40% who had recently experienced a heart failure hospitalization. Patients received elamipretide 4 mg/hour IV for the first four hours, followed by elamipretide 0.01 mg/kg/hour for 72 hours, or placebo. The primary endpoint, change in left ventricular end-systolic volume at day 28, did not achieve statistical significance 8.

Post-hoc analyses suggested improvements in certain echocardiographic parameters, but the trial was underpowered for definitive conclusions.

MMPOWER Trials: Primary Mitochondrial Myopathy

MMPOWER-3 (NCT03323749) was a Phase 3, randomized, double-blind trial in 218 patients with primary mitochondrial myopathy. Patients received elamipretide 40 mg subcutaneously once daily or placebo for 24 weeks. The co-primary endpoints were change from baseline in 6MWT distance and the Primary Mitochondrial Myopathy Symptom Assessment total fatigue score. Neither primary endpoint reached statistical significance (P = 0.11 for 6MWT; P = 0.52 for fatigue score) 9.

This was the largest randomized trial of any mitochondria-targeted peptide. Its failure to meet primary endpoints raised questions about whether the clinical trial design or the drug's efficacy was the limiting factor.

Safety and Side Effects

Across completed trials, the most commonly reported adverse events with elamipretide were injection-site reactions (erythema, pain, and pruritus in roughly 30 to 50% of patients on active treatment). These were generally mild and did not lead to discontinuation 6.

Systemic Tolerability

Serious adverse events occurred at similar rates in elamipretide and placebo groups across TAZPOWER and MMPOWER-3. No dose-limiting organ toxicity was observed in Phase 1 dose-escalation studies up to 0.25 mg/kg single-dose IV 10. Renal and hepatic panels remained stable throughout treatment periods.

Open Questions

Long-term safety data beyond two years remain limited. Injection-site reactions are the primary tolerability concern. Whether chronic daily subcutaneous dosing causes local tissue changes (lipodystrophy, fibrosis) over years of use is unknown.

SS-31 in the Context of Other Specialty Peptides

SS-31 belongs to a growing class of peptides targeting aging-related biology. Several related compounds are at various stages of investigation. Understanding where each one fits helps clarify what SS-31 does and does not do.

Epitalon

Epitalon (epithalon, AEDG peptide) is a synthetic tetrapeptide modeled after epithalamin, a pineal gland extract. It is claimed to activate telomerase and lengthen telomeres in human cell cultures 11. The available evidence comes primarily from studies by Vladimir Khavinson's group in Russia. No randomized controlled trials in humans have been registered on ClinicalTrials.gov, and the peptide has no FDA investigational new drug application on record. Epitalon does not target mitochondria; its proposed mechanism involves gene expression regulation in the pineal gland.

MOTS-c

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA (within the 12S rRNA gene). It activates AMPK and has been shown in mouse models to improve insulin sensitivity and exercise capacity 12. Unlike SS-31, MOTS-c is a mitochondrial-derived peptide (MDP) rather than a synthetic molecule designed to target mitochondria from outside. Phase 1 human data are not yet available.

Humanin

Humanin is a 24-amino-acid MDP also encoded in mitochondrial DNA (16S rRNA gene). It acts as an anti-apoptotic factor and has been studied in models of Alzheimer's disease, type 2 diabetes, and age-related macular degeneration 13. Circulating humanin levels decline with age, and higher levels have been associated with longer lifespan in epidemiological studies. No clinical trials testing exogenous humanin administration have been completed.

FOXO4-DRI

FOXO4-DRI is a cell-penetrating peptide designed to disrupt the FOXO4-p53 interaction that maintains senescent cell viability. In aged mice, it selectively induced apoptosis in senescent cells and restored fur density, renal function, and fitness 14. It is a senolytic agent, not a mitochondrial-targeted peptide. No human clinical trials have been registered. The peptide is expensive to synthesize and the optimal dose, route, and frequency in humans are entirely unknown.

Comparison Table

| Peptide | Target | Mechanism | Human Trial Data | FDA Status | |---|---|---|---|---| | SS-31 (elamipretide) | Cardiolipin, inner mitochondrial membrane | Stabilizes electron transport, reduces ROS | Phase 2/3 completed | Not approved (CRL 2023) | | Epitalon | Telomerase (proposed) | Telomere elongation (in vitro) | None registered | No IND | | MOTS-c | AMPK pathway | Insulin sensitization, exercise mimetic | None completed | No IND | | Humanin | BAX, IGFBP-3 | Anti-apoptotic, cytoprotective | None completed | No IND | | FOXO4-DRI | FOXO4-p53 interaction | Senolytic (senescent cell clearance) | None registered | No IND |

Regulatory Status and the FDA Peptide Field

The FDA's 2023 decision to restrict certain bulk drug substances from 503A and 503B compounding pharmacies affected multiple peptides. SS-31/elamipretide was not among the compounds explicitly listed for removal from the bulk drug substance nomination list, because it has been under active investigation with an IND. However, access outside of clinical trials remains restricted.

The Compounding Problem

Compounding pharmacies have marketed "SS-31" or "elamipretide" to consumers, but the purity and potency of these products are unverified. The four-amino-acid sequence is relatively simple to synthesize, which lowers the barrier for gray-market production. Stealth BioTherapeutics holds patents on the compound's pharmaceutical use, making unauthorized commercial sale a legal and safety concern 15.

What Comes Next

Stealth BioTherapeutics has indicated plans to continue development, potentially with a revised clinical strategy for Barth syndrome or a new indication. The company's pipeline also includes ophthalmic formulations of elamipretide for age-related macular degeneration (ReCLAIM trials), though Phase 2 results were mixed 16.

Practical Considerations for Patients and Clinicians

SS-31 is not available by prescription in the United States. Patients who encounter it through compounding pharmacies or online peptide vendors should be aware of three realities.

Purity Is Unverified

Without FDA-approved manufacturing standards, compounded SS-31 may contain misfolded peptide, endotoxin, or degradation products. Independent third-party certificates of analysis (COAs) are not a substitute for GMP manufacturing.

Dosing Is Not Established

Clinical trials used 40 mg subcutaneously once daily for Barth syndrome and primary mitochondrial myopathy. Whether this dose applies to off-label uses (aging, athletic recovery, neuroprotection) is unknown. Extrapolating from disease-specific trials to general wellness is not supported by evidence.

Monitoring Has No Standard

No biomarker panel is validated for tracking SS-31 response in clinical practice. Lactate, creatine kinase, and mitochondrial respiratory chain enzyme activities have been used in research settings but are not practical or specific enough for routine outpatient monitoring.

The Bottom Line on Mitochondrial Peptides

SS-31 represents the most clinically advanced mitochondria-targeted peptide. It has a clear molecular target (cardiolipin), a well-characterized mechanism, and over 800 patients enrolled across completed trials. Yet it remains unapproved, primarily because clinical endpoints in heterogeneous mitochondrial diseases have been difficult to move with statistical significance.

Among the related specialty peptides, only SS-31 has reached Phase 3 human testing. Epitalon, MOTS-c, humanin, and FOXO4-DRI remain at the preclinical or very early investigational stage. Any claims that these peptides are proven therapies for aging, cancer, or neurodegeneration outpace the published evidence.

Patients considering any of these compounds should discuss them with a physician familiar with mitochondrial medicine. The Mitochondrial Medicine Society maintains a clinical provider directory referenced through their published care standards. For Barth syndrome specifically, the Barth Syndrome Foundation tracks clinical trial enrollment opportunities.

The 40 mg daily subcutaneous dose of elamipretide that showed a 29.6-meter 6MWT improvement in TAZPOWER 6 remains the single best-supported dosing regimen for any mitochondria-targeted peptide in any human disease.